# Neurocognitive and health-related quality of life outcomes of nocturnal oxygen supply in chronic obstructive pulmonary disease patients with sleep-related oxygen desaturation

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
07/03/2006	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
11/04/2006	Completed	Results
Last Edited	Condition category	Individual participant data
11/04/2006	Respiratory	<ul><li>Record updated in last year</li></ul>

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Susana Mota

#### Contact details

Hospital Santa Caterina Hospital de Dia Dr. Castany, s/n Salt Spain 17019 +34 (0)97 218 26 00 susana.mota@ias.scs.es

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

### Secondary identifying numbers

IAS-PnN1-2006

# Study information

Scientific Title

#### Acronym

**GIRON** 

#### Study objectives

Nocturnal oxygen supply will prevent the consequences of sleep-related hypoxemia (i.e. neurocognitive and health-related quality of life decline) in severe to very severe chronic obstructive pulmonary disease (COPD) patients presenting sleep-related oxygen desaturation. This decline will become similar to that seen in those severe to very severe COPD patients without nocturnal desaturation.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Approved by the Institute of Health Assistance (Institut d'Assistència Sanitària) (IAS), Institutional Review Board (IRB) reviewed the protocol and reported its approval on 27/04/2004, reference number: CEIC-IAS 06/2004

## Study design

Prospective, randomised clinical trial and prospective case-control study

## Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Not specified

# Study type(s)

**Treatment** 

#### Participant information sheet

## Health condition(s) or problem(s) studied

COPD with and without nocturnal desaturation

#### **Interventions**

All patients will receive standard care, but nocturnal desaturators will be randomized to receive oxygen during sleep or standard care only. Neurocognitive function, blood/urine analysis and electrocardiogram will be assessed at baseline and at 18 months. Health-related quality of life,

lung function, six-minute walking test, nocturnal oxymetry and respiratory and sleep-related symptoms will be assessed at baseline and at six-month intervals.

#### Intervention Type

Other

#### **Phase**

**Not Specified** 

#### Primary outcome measure

Neurocognitive function by means of a battery of tests:

- 1. Trail making test
- 2. Wechsler adult intelligence scale (WAIS)
- 3. Wechsler memory scale-revised (WMSR) test
- 4. Verbal fluency test
- 5. Rev complex figure test (RCFT)
- 6. Rey auditory verbal learning test (RAVLT)
- 7. National adult reading test (NART)
- 8. Repeatable battery for the assessment of neuropsychological status (RBANS)
- 9. Luria's premotor test performance

#### Secondary outcome measures

- 1. Health-related quality of life (St. George's respiratory questionnaire)
- 2. Anxiety (state-trait anxiety inventory [STAI])
- 3. Depression (Beck depression inventory [BDI])
- 4. Exercise capacity (walking test)
- 5. Sleepiness (Epworth scale)
- 6. Dyspnea (Medical Research Council [MRC] scale)
- 7. Diurnal oxygen and carbonic anhydride blood pressures
- 8. Nocturnal urinary norepinephrine
- 9. Exacerbation rate
- 10. Hospitalization days
- 11. Mortality

#### Overall study start date

08/03/2006

#### Completion date

07/03/2009

# **Eligibility**

#### Key inclusion criteria

- 1. Severe to very severe stable COPD
- 2. Age 60 to 80 years
- 3. With a resting awake pO2 between 60 and 80 mmHg, with (cases) or without (controls) sleep-related oxygen desaturation

#### Participant type(s)

Patient

#### Age group

Adult

#### Sex

Both

# Target number of participants

216 (144 nocturnal desaturators)

#### Key exclusion criteria

- 1. Clinically significant obstructive sleep apnea-hypopnea syndrome
- 2. Alcoholism
- 3. Anemia
- 4. Dementia
- 5. Cirrhosis
- 6. Obesity
- 7. Active psychiatric disease
- 8. Abnormal thyroid function
- 9. Stroke
- 10. Chronic systemic steroid therapy
- 11. Malignancy

#### Date of first enrolment

08/03/2006

#### Date of final enrolment

07/03/2009

# Locations

# Countries of recruitment

Spain

# Study participating centre Hospital Santa Caterina

Salt

Spain

17019

# Sponsor information

#### Organisation

Institute of Health Assistance (Institut d'Assistència Sanitària [IAS]) (Spain)

# Sponsor details

Parc Hospitalari Marti i Julia Dr. Castany, s/n Salt Spain 17019 +34 (0)97 218 26 00 recerca@ias.scs.es

#### Sponsor type

Industry

#### Website

http://www.ias.scs.es

#### **ROR**

https://ror.org/058css875

# Funder(s)

# Funder type

Industry

#### Funder Name

IAS

#### **Funder Name**

Grants from:

#### **Funder Name**

Catalan Society of Pneumology 2005 (Societat Catalana de Pneumologia [SOCAP] 2005)

#### Funder Name

Spanish Society of the Pathology of the Respiratory System 2005 (Sociedad Española de Patología del Aparato Respiratorio [SEPAR] 2005)

#### Funder Name

Spanish Company of Air Products and Chemicals Inc. (Sociedad Española de Carburos Metálicos S. A.)

# **Results and Publications**

**Publication and dissemination plan**Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration